(Abstracted from Am J Obstet Gynecol 2017;216:500.e1–500.e11)
Although uterine fibroids are a common problem among reproductive-aged women, few comparative effectiveness studies are available to guide treatment decisions. Two minimally invasive treatments—uterine artery embolization (UAE) and magnetic resonance imaging–guided focused ultrasound surgery (MRgFUS)—have been approved by the US Food and Drug Administration for treatment of symptomatic uterine fibroids.
Departments of Obstetrics and Gynecology (E.P.B., A.M.A., S.K.L.-T., B.J.B., E.A.S.), Radiology (G.K.H., D.A.W., K.R.G.), and Research Administration (L.G.P.), and Divisions of Biomedical Statistics and Informatics (L.E.V., A.L.W.) and Health Care Policy and Research (B.J.B.), Mayo Clinic, Rochester, MN; Departments of Obstetrics, Gynecology, and Reproductive Sciences (V.L.J.) and Radiology and Biomedical Imaging (M.P.K.), University of California, San Francisco, San Francisco, CA; Departments of Obstetrics and Gynecology (T.M.P., A.N., P.C.L.) and Radiology (M.J.M.), Duke University, Durham, NC; and Department of Obstetrics and Gynecology, Women’s Health Hospital, Assiut University, Assiut, Egypt (A.M.A.)